Modulation of vestibular function by nociceptin/orphanin FQ: an in vivo and in vitro study

Sulaiman, Mohd Roslan; Niklasson, Magnus; Tham, Richard; Dutia, Mayank B.

doi:10.1016/s0006-8993(99)01331-1

Cited by 30 publications

(12 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, functional evidence also supports cellular colocalization of KOR/NOP receptor in PAG and RVM, suggesting that KOR/NOP receptor heterodimerization may mediate nociceptive processing (Vaughan et al, 2001(Vaughan et al, , 2003. DOR and NOP receptors colocalize at the cellular level in neurons in the PAG and the medial vestibular nucleus (Sulaiman et al, 1999;Vaughan et al, 2003), suggesting that heterodimers may modulate nociceptive processing and vestibular reflex.…”

Section: Heterodimerizationmentioning

confidence: 86%

Cellular Mechanisms of Nociceptin/Orphanin FQ (N/OFQ) Peptide (NOP) Receptor Regulation and Heterologous Regulation by N/OFQ

et al. 2013

View full text Add to dashboard Cite

The nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor is the fourth and most recently discovered member of the opioid receptor superfamily that also includes m, d, and k opioid receptor subtypes (MOR, DOR, and KOR, respectively). The widespread anatomic distribution of the NOP receptor enables the modulation of several physiologic processes by its endogenous agonist, N/OFQ. Accordingly, the NOP receptor has gained a lot of attention as a potential target for the development of ligands with therapeutic use in several pathophysiological states. NOP receptor activation frequently results in effects opposing classic opioid receptor action; therefore, regulation of the NOP receptor and conditions affecting its modulatory tone are important to understand. Mounting evidence reveals a heterologous interaction of the NOP receptor with other G protein-coupled receptors, including MOR, DOR, and KOR, which may subsequently influence their function. Our focus in this review is to summarize and discuss the findings that delineate the cellular mechanisms of NOP receptor signaling and regulation and the regulation of other receptors by N/OFQ and the NOP receptor.

show abstract

Section: Heterodimerizationmentioning

confidence: 86%

Cellular Mechanisms of Nociceptin/Orphanin FQ (N/OFQ) Peptide (NOP) Receptor Regulation and Heterologous Regulation by N/OFQ

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Since the neurological impairment was essentially similar between the species, these data would seem to suggest that certain physiological changes produced as a result of ORL-1 receptor activation are more deleterious to the mouse compared to rat. Conceivably, these may be related to changes in thermoregulation, or motor, cardiovascular, vestibular, and/or renal function, each of which have been shown to be influenced by exogenously administered ORL-1 receptor agonists (Devine et al 1996b;Champion and Kadowitz 1997;Sulaiman et al 1999;Kapusta et al 1999;Higgins et al 2001;Marti et al 2004).…”

Section: Discussionmentioning

confidence: 99%

Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species

Varty¹,

Hyde²,

Hodgson³

et al. 2005

Psychopharmacology

View full text Add to dashboard Cite

Ro64-6198 (3-10 mg/kg) increased punished responding in a rat conditioned lick suppression test similarly to chlordiazepoxide (6 mg/kg). This effect of Ro64-6198 was attenuated by J-113397 (10 mg/kg), but not the mu opioid antagonist, naltrexone (3 mg/kg). In addition, Ro64-6198 (1-3 mg/kg) reduced isolation-induced vocalizations in rat and guinea pig pups. Ro64-6198 (3 mg/kg) increased the proportion of punished responding in a mouse Geller-Seifter test in wild-type (WT) but not ORL-1 KO mice, whereas diazepam (1-5.6 mg/kg) was effective in both genotypes. In rats, Ro64-6198 reduced locomotor activity (LMA) and body temperature and impaired rotarod, beam walking, and fixed-ratio (FR) performance at doses of 10-30 mg/kg, i.e., three to ten times higher than an anxiolytic dose. In WT mice, Ro64-6198 (3-10 mg/kg) reduced LMA and rotarod performance, body temperature, and FR responding, but these same measures were unaffected in ORL-1 KO mice. Haloperidol (0.3-3 mg/kg) reduced these measures to a similar extent in both genotypes. These studies confirm the potent, ORL-1 receptor-mediated, anxiolytic-like effects of Ro64-6198, extending the findings across three species. Ro64-6198 has target-based side effects, although the magnitude of these effects varies across species.

show abstract

“…2 ). Among these are GABA-A and GABA-B receptors and glycine receptors that show an extensive colocalization with GABA receptors, histamine H 1 , H 2 and H 3 receptors [15], serotonine 5HT 1 and 5HT 2 receptors [56], adrenergic α2 receptors, but also α1 and β receptors [124], cholinergic muscarinic (mACh) and nicotinic (nACh) receptors in all the vestibular nuclei [92], opioid receptors [146, 147], canabinoid CB1 receptors [132], neurotrophin Trk A, B and C receptors (for a review, see [27]) and finally, glucocorticoid receptors.…”

Section: Drugs With Effects On Neurotransmitters and Neuromodulator Rmentioning

confidence: 99%

Neuropharmacology of Vestibular System Disorders

Soto¹,

Vega²

2010

View full text Add to dashboard Cite

This work reviews the neuropharmacology of the vestibular system, with an emphasis on the mechanism of action of drugs used in the treatment of vestibular disorders. Otolaryngologists are confronted with a rapidly changing field in which advances in the knowledge of ionic channel function and synaptic transmission mechanisms have led to the development of new scientific models for the understanding of vestibular dysfunction and its management. In particular, there have been recent advances in our knowledge of the fundamental mechanisms of vestibular system function and drug mechanisms of action. In this work, drugs acting on vestibular system have been grouped into two main categories according to their primary mechanisms of action: those with effects on neurotransmitters and neuromodulator receptors and those that act on voltage-gated ion channels. Particular attention is given in this review to drugs that may provide additional insight into the pathophysiology of vestibular diseases. A critical review of the pharmacology and highlights of the major advances are discussed in each case.

show abstract

Modulation of vestibular function by nociceptin/orphanin FQ: an in vivo and in vitro study

Cited by 30 publications

References 43 publications

Cellular Mechanisms of Nociceptin/Orphanin FQ (N/OFQ) Peptide (NOP) Receptor Regulation and Heterologous Regulation by N/OFQ

Cellular Mechanisms of Nociceptin/Orphanin FQ (N/OFQ) Peptide (NOP) Receptor Regulation and Heterologous Regulation by N/OFQ

Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species

Neuropharmacology of Vestibular System Disorders

Contact Info

Product

Resources

About